Rocket Pharmaceuticals, Inc. Capital Expenditures Incurred but Not yet Paid
Rocket Pharmaceuticals, Inc. (RCKT) reported Capital Expenditures Incurred but Not yet Paid of $75.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $75.00K, a 38.52% decline year-over-year.
- Rocket Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $0.00.
- Rocket Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$173.00K.
- Rocket Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Rocket Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $185.00K, a 82.82% decline from fiscal 2023.
- Rocket Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $1.08M, a 48.59% decline from fiscal 2022.
- Rocket Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $2.10M, a 187.77% increase from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 6 month as first filed | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $75.00K 10-Q · filed 2026-08-10 | $75.00K derived: sum of 3 quarters · filed 2026-08-10 | -$98.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | -$173.00K derived: sum of 3 quarters · filed 2026-05-07 | -$51.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$173.00K derived: sum of 2 quarters · filed 2026-02-26 | -$51.00K derived: sum of 3 quarters · filed 2026-08-10 | $0.00 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$173.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$51.00K derived: sum of 2 quarters · filed 2026-08-10 | $0.00 10-Q · filed 2025-11-06 | -$80.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $122.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $173.00K 10-Q · filed 2026-08-10 | $0.00 10-Q · filed 2025-08-07 | $93.00K derived: sum of 3 quarters · filed 2026-08-10 | -$678.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $51.00K 10-Q · filed 2026-05-07 | -$29.00K derived: sum of 2 quarters · filed 2026-05-07 | -$800.00K derived: sum of 3 quarters · filed 2026-05-07 | -$687.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$851.00K derived: sum of 2 quarters · filed 2026-02-26 | -$738.00K derived: sum of 3 quarters · filed 2026-02-26 | $185.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$771.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$658.00K derived: sum of 2 quarters · filed 2025-11-06 | $265.00K 10-Q · filed 2025-11-06 | -$328.00K derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.04M 10-Q · filed 2025-08-07 | $443.00K derived: sum of 3 quarters · filed 2025-08-07 | $848.00K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $923.00K 10-Q · filed 2025-05-08 | $330.00K derived: sum of 2 quarters · filed 2025-05-08 | $735.00K derived: sum of 3 quarters · filed 2025-05-08 | $206.00K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$593.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$188.00K derived: sum of 2 quarters · filed 2025-02-27 | -$717.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.08M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $405.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$124.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.67M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$529.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.26M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $1.79M 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | $2.10M 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $702.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $606.00K derived: sum of 2 quarters · filed 2024-02-27 | $417.00K derived: sum of 3 quarters · filed 2024-02-27 | $728.00K 10-K · filed 2024-02-27 | |
| 2021-09-30 | -$96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$285.00K derived: sum of 2 quarters · filed 2021-11-05 | $26.00K 10-Q · filed 2021-11-05 | $226.00K derived: sum of 4 quarters · filed 2021-11-05 | |
| 2021-06-30 | -$189.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $122.00K 10-Q · filed 2021-08-09 | $322.00K derived: sum of 3 quarters · filed 2021-08-09 | $300.00K derived: sum of 4 quarters · filed 2021-11-05 | |
| 2021-03-31 | $311.00K 10-Q · filed 2021-05-10 | $511.00K derived: sum of 2 quarters · filed 2021-05-10 | $489.00K derived: sum of 3 quarters · filed 2021-11-05 | $437.00K derived: sum of 4 quarters · filed 2021-11-05 | |
| 2020-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $178.00K derived: sum of 2 quarters · filed 2021-11-05 | $126.00K derived: sum of 3 quarters · filed 2021-11-05 | $300.00K 10-K · filed 2021-03-01 | |
| 2020-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$74.00K derived: sum of 2 quarters · filed 2021-11-05 | $100.00K 10-Q · filed 2021-11-05 | $326.00K derived: sum of 4 quarters · filed 2021-11-05 | |
| 2020-06-30 | -$52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $122.00K 10-Q · filed 2021-08-09 | $348.00K derived: sum of 3 quarters · filed 2021-08-09 | $348.00K derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $174.00K 10-Q · filed 2021-05-10 | $400.00K derived: sum of 2 quarters · filed 2021-05-10 | $400.00K derived: sum of 3 quarters · filed 2021-05-10 | $400.00K derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | $226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $226.00K derived: sum of 2 quarters · filed 2021-03-01 | $226.00K derived: sum of 3 quarters · filed 2021-03-01 | $226.00K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $0.00 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-08 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |